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ABSTRACT
High-throughputgenetrappingisarandomapproach
for inducing insertional mutations across the mouse
genome. This approach uses gene trap vectors that
simultaneously inactivate and report the expression
of the trapped gene at the insertion site, and provide
a DNA tag for the rapid identification of the disrupted
gene. Gene trapping has been used by both public
and private institutions to produce libraries of
embryonic stem (ES) cells harboring mutations in
single genes. Presently,  66% of the protein coding
genes in the mouse genome have been disrupted by
gene trap insertions. Among these, however, genes
encodingsignalpeptidesortransmembranedomains
(secretory genes) are underrepresented because
they are not susceptible to conventional trapping
methods. Here, we describe a high-throughput gene
trapping strategy that effectively targets secretory
genes. We used this strategy to assemble a library
of ES cells harboring mutations in 716 unique
secretory genes, of which 61% were not trapped by
conventional trapping, indicating that the two
strategies are complementary. The trapped ES cell
lines, which can be ordered from the International
Gene Trap Consortium (http://www.genetrap.org),
are freely available to the scientific community.
INTRODUCTION
High-throughput gene trapping is a random approach for
inducing insertional mutations across the mouse genome.
This approach uses gene trap vectors whose principal element
is a gene trapping cassette consisting of a promoterless
reporter and/or selectable marker gene ﬂanked by an upstream
30 splice site [splice acceptor (SA)] and a downstream tran-
scriptional termination sequence [polyadenylation sequence
(polyA)]. When inserted into an intron of an expressed
gene, the gene trap cassette istranscribed from the endogenous
promoterin the form of a fusion transcript inwhich the exon(s)
upstream of the insertion site is spliced to the reporter/select-
able marker gene. Since transcription is terminated prema-
turely at the inserted polyadenylation site, the processed
fusion transcript encodes a truncated and non-functional ver-
sion of the cellular protein and the reporter/selectable marker
(1). Thus, gene traps simultaneously inactivate and report the
expression of the trapped gene at the insertion site and provide
a DNA tag [gene trap sequence tag (GTST)] for the rapid
identiﬁcation of the disrupted gene.
Gene trap approaches have been used successfully in the
past by both academic and private organizations to create
libraries of ES cell lines harboring mutations in single
genes that can be used for making mice (2–5). Presently,
the existing public resources put together by the International
Gene Trap Consortium (IGTC) contain over 40000 ES cell
lines covering  40% of the protein coding genes expressed in
the mouse genome (6). While most functional gene classes are
represented, these libraries are biased against mutations in
secretory pathway genes because the acquisition of a signal
sequence by a gene trap induced fusion protein leads to its
secretion and failure to report the trapping event. The muta-
tional analysis of secretory pathway genes is highly desirable
for two main reasons. First, they control intercellular commu-
nications and play a major role in most known signal trans-
duction pathways and are, therefore, frequently involved in the
pathogenesis of human disease. Second, the proteins are easily
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To mutate secretory genes more effectively in mammalian
cells, we and others have developed gene trap vectors that are
activatedonlyaftercapturingasignalsequenceoratransmem-
brane domain from an endogenous gene (7–9). Typically,
these vectors contain a transmembrane domain (TM) upstream
of a marker gene, which anchors the gene trap fusion protein in
the cell membrane.
We have previously shown that the retroviral gene trap
vector -U3Ceo- traps secretory genes with high efﬁciency
in somatic cells (9). Here, we show that this vector and its
conditional variant -FlipRosaCeo- (10) trap secretory genes
with similar efﬁciency in ES cells and induce null mutations
with a frequency comparable to other gene trap vectors. We
have used these vectors to assemble the largest library of ES
cell lines with mutations in secretory genes yet assembled,
presently totaling 717 unique genes. Most importantly,
more than half of these genes have not been trapped before,
underscoring the utility of secretory trapping for the cost-
effective saturation mutagenesis ofthe mouse genome (11,12).
MATERIALS AND METHODS
Plasmids
The U3Ceo gene trap vector was obtained as previously
described by inserting a CD2/neomycin-phosphotransferase
fusion gene (Ceo) into the U3 region a promoter- and enhan-
cerless Moloney murine leukemia virus (9,10). To obtain Ceo
cassettes speciﬁc for each translational reading frame, the
original pU3Ceo vector speciﬁc for the second reading
frame (U3Ceo
2) (9,10) was modiﬁed as follows: to obtain
U3Ceo
1 for trapping the ﬁrst reading frame, the oligonuc-
leotides 50-acgaatgcc-30 and 50-cattcgtgt-30 were annealed
and cloned into the unique BsmI and BsgI sites of pU3Ceo.
To obtain U3Ceo
3 for trapping the third reading frame,
pU3Ceo was cleaved with BsmI and re-ligated after removing
the 30 overhangs with T4-DNA polymerase (New England
Biolabs, Frankfurt am Main, Germany). FlipRosaCeo vectors
were derived from FlipRosabgeo (10) by replacing the
SAbgeo cassette with the frame-speciﬁc Ceo cassettes.
ES cell cultures and infections
The [C57BL/6J · 129S6/SvEvTac]F1 and [129/SvPas]
TBV-2 ES cell lines were grown on irradiated or mito-
mycin C-treated MEF feeder layers in the presence of 1000–
1500U/mlleukemiainhibitoryfactor(LIF) (Esgro,Chemicon,
Hofheim, Germany) as described previously (4,10).
For mutational analysis, ES cells were trypsinized and
seeded onto gelatinized plates. After incubating for 1 h, the
slower sedimenting and less adherent feeder cells were
removed by gentle washing followed by a medium change.
This procedure was repeated for three passages before RNA
extraction.
For embryoid body cultures, ES cells were grown for 8 days
in bacterial culture dishes without LIF and feeder layers.
Embryoid bodies were recovered by centrifugation, trypsin-
izedand grown on gelatinized tissue culture plates for a further
2–3 days before RNA extraction.
Gene trap retrovirus was produced in Phoenix-Eco helper
cells by using the transient transfection strategy described
previously (10). ES cells were infected with the virus-
containing supernatants at a multiplicity of infection of
<0.5. Gene trap expressing ES cell lines were selected in
130 mg/ml (F1) or in 150 mg/ml (TBV-2) G418 (Invitrogen,
Karlsruhe, Germany), manually picked, expanded and stored
frozen in liquid nitrogen.
Gene expression analyses
RT–PCRs were performed according to the standard protocols
by using 75 ng of reverse-transcribed total RNA in a total
volume of 50 ml. Real-time RT–PCR analysis of gene expres-
sion in ES cells was performed using SYBR green chemistry
(ABgene, Epsom, UK) and an iCycler (Biorad) machine.
cDNA was synthesized from total RNA using random priming
and Superscript II (Invitrogen) reverse transcriptase. Primers
(20–22mer) ﬂanking the gene trap insertion site were designed
to span at least one intron and to amplify fragments between
100 and 250 nt. PCRs were run as triplicates on 96-well plates,
with each reaction containing cDNA derived from 7.5 to 15 ng
of total RNA, 5 pmol of each primer and 1· ABsolute SYBR
ﬂuorescein mix (ABGene) in a 25 ml volume. The temperature
proﬁle was 10 min at 95 C and then 40 cycles at 94 C for
15 s, 61 C for 30 s and 72 C for 30 s. Gene-speciﬁc primer
sequences are listed in Supplementary Table 3. Generic
primers are available on request.
For northern blotting, total RNA was extracted from tissue
by using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. The RNA
(20 mg) was fractionated on 1% formaldehyde/agarose gels,
blottedontoHybondN+(AmershamBiosciences)nylonmem-
branes and hybridized to
32P-labeled cDNA probes (Hartmann
Analytic, Braunschweig, Germany) in ULTRAhyb hybridiza-
tion solution (Ambion, Austin, TX) according to the manufac-
turer’s instructions. The C030019F02Rik-cDNA probe was
obtained by asymmetric RT–PCR using an antisense primer
complementary to exon 7 of the C030019F2Rik gene (10).
Semiautomated 50-rapid ampliﬁcation of cDNA ends
(50-RACE) and sequencing were performed as described by
Hansen et al. (4).
CD2 antibody staining and FACS analysis
A total of 10
6 cells were suspended in 50 ml phosphate-
buffered saline (PBS) (Invitrogen, Karlsruhe, Germany)
and incubated for 30 min at 4 C with 2.5 mg/ml of
CD2-speciﬁc mouse monoclonal antibody Leu-5b (Becton
Dickinson, Heidelberg, Germany). Subsequently, the cells
were incubated for 30 min at 4 Ci n5 0ml PBS containing
10% (v/v) ﬂuorescein isothiocyanate (FITC)-conjugated sheep
anti-mouse-Fab02 antibody (Chemicon, Limburg, Germany).
Finally, cells were suspended in 500 ml of 2% formaldehyde in
PBS and analyzed in a FACScan(Becton Dickinson) ﬂow
cytometer.
GTST analysis
GTSTs were analyzed as described previously (4) by using
the following databases: BayGenomics (http://baygenomics.
ucsf.edu), GenBank (release 150), Unigene (built 150),
RefSeq (release 13) (all at http://www.ncbi.nlm.nih.gov),
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informatics.jax.org), GeneOntology (October 2005 release)
(http://www.geneontology.org), SMART version 4.1 (http://
smart.embl-heidelberg.de) and TargetP version 1.1 (http://
www.cbs.dtu.dk).
ES cell injections, breeding and genotyping
M076C04 (TBV-2; 129SvPas) and G033C05 (F1; C57BL6/
j · 129S6/SvEvTac) ES cell derived chimeras were generated
by injecting C57Bl/6 blastocysts. The resulting male chimeras
were bred to C57Bl/6 females, and F1 agouti offspring
containing the disrupted transgene were intercrossed to obtain
homozygous F2 mice. Genotyping was performed on mouse
tail DNA by PCR using primers against the sequences ﬂanking
the gene trap insertion previously identiﬁed in ES cells by
inverse PCR and sequencing.
RESULTS
Assembly of an ES cell library with mutations in
secretory genes
We used the retroviral gene trap vectors U3Ceo and Fli-
pRosaCeo (Figure 1) to transduce the promoterless reporter
gene -Ceo- into mouse ES cells in all three translational
reading frames. Both vectors are promoter and enhancerless
Moloney murine leukemia viruses with the -Ceo- gene inser-
ted either in the U3 region of the retroviral LTR (U3Ceo) or
in the body of the virus between the LTRs (FlipRosaCeo)
(Figure 1) (10). The Ceo gene is an in-frame fusion between
an ATG-less, C-terminally truncated human CD2 receptor
cDNA and the neomycinphosphotransferase gene (neo).
The CD2 moiety of the fusion gene provides a type II
transmembrane domain (TM) and an N-terminal cryptic splice
acceptor sequence, which has been shown to effectively
induce splicing when inserted into an intron of an expressed
gene (13). Productive insertions into secretory genes require
capture of a signal sequence or a transmembrane domain
to invert the default inside/out (type II) transmembrane ori-
entation of the Ceo protein so that its catalytic C-terminus is
placed into the cytosol where it confers G418 resistance.
To test the trapping efﬁciency of the three frame-speciﬁc
U3Ceo vectors, we initially used them individually to produce
783 cell lines with U3Ceo
1, 831 with U3Ceo
2 and 463 with
U3Ceo
3, yielding insertions in the ﬁrst, second and third trans-
lational reading frame, respectively. GTST recovery by
50-RACE (4) and database analysis revealed that of the
439 genes recovered, 332 (76%) were trapped in one frame
only. Moreover, an equal fraction of unique genes were
trapped in each frame-speciﬁc library (i.e.  30%), suggesting
that reading frames are evenly distributed between secretory
genes. Overall, only 24% of the genes were trapped in
more than one reading frame. Thus, a substantial number
of trappable genes are missed by each of the frame-speciﬁc
vectors andthereforewe used pools ofall threetocomplete the
library production.
Overall, we isolated 4569 ES cell lines with secretory
trap insertions and recovered 4167 GTSTs, of which 3260
were derived from U3Ceo- and 907 from FlipRosaCeo
insertions.
In silico analysis employing a combination of SMART
(http://smart.embl-heidelberg.de) and TargetP (http://www.
cbs.dtu.dk) software revealed that 80% of all insertions
were in secretory genes. Of these, 33% encoded a signal pep-
tide, 24% a signal peptide and a transmembrane domain, 11%
a type II transmembrane domain and 12% a mitochondrial
protein. The remaining 20% encoded neither a signal peptide
nor a transmembrane domain. RT–PCR analysis of several
non-secretory trap events revealed that in each case the
CD2 transmembrane domain was either partly or completely
lost from the cell-provirus fusion transcript as a result of
aberrant splicing (data not shown).
Ninety-six percent of the U3Ceo- and 99% of the
FlipRosaCeo GTSTs belonged to known genes. A total of
717 unique genes were trapped, of which 440 have not
been trapped by any of the conventional strategies applied
by the IGTC or by the biotechnology company -Lexicon
Genetics- (2,6) (Table 1).
Secretory gene trapping rates were consistently inferior
to the conventional trapping rates and decreased more quickly
with accumulating integrations (6). On average, the Ceo
vectors needed more than twice as many insertions to trap
a novel gene than, for example, the conventional gene trap
vector Rosabgeo (14) (Figure 2). This inferior secretory
trapping rate is due to signiﬁcantly smaller genomic and
intragenic integration targets: genomic, because only 1/3 of
all coding genes encode secretory proteins according to
the ENSEMBL database; intragenic, because productive
Figure 1. Schematic representation of the secretory gene trap vectors. LTR,
longterminalrepeat;Ceo,CD2/neomycinphosphotransferase fusiongene; SA,
splice acceptor; TM, transmembrane domain; frt (yellow triangles) and F3
(green triangles) heterotypic target sequences for FLPe recombinase; loxP
(red triangle) and lox511 (purple triangles), heterotypic target sequences from
Cre recombinase.
Table 1. Summary of results obtained with the secretory gene trap vectors
a
Gene trap vector U3Ceo FlipRosaCeo Total
Number of ES cell lines 3620 949 4569
Number of GTSTs 3260 907 4167
Number of insertions into
annotated genes
3144 898 4042 (97.0%)




Number of ‘hot spots’
b 281 95 343 (45%)
c
aAnalysis based on NCBI mouse genome build 34 and RefSeq release 13.
bAll genes with >2 insertions were classified as hot spots.
cGenes and hot spots trapped by both vectors have been counted only once.
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Secretory trap insertions are not entirely random
Secretory traps insert into all chromosomes except the Y
chromosome and have a preference for chromosomes with
a high density of genes. As shown in Figure 3, the number
of secretory trap insertions per chromosome is correlated with
the number of genes on that chromosome, which is similar to
the previously reported insertion pattern of conventional gene
trap vectors (4).
As expected from the reported preference of retroviral
integrations near the 50 end of genes and from observations
made in previous trapping screens, the majority of the secret-
ory trap insertions occurred into the ﬁrst or second intron of
a gene (Figure 4) (4,15).
Similar to their conventional counterparts, secretory gene
traps have several preferred insertion sites or integration ‘hot
spots’ across the mouse genome. Almost half of the trapped
secretory genes contained two or more insertions, and some
were hit up to 50 times. Examples include the serine
carboxypeptidase 1 (Scpep1/Accession no. NM_029023)
with 50 insertions, cadherin 1 (Cdh1/Accession no.
NM_009864) with 42, the protein tyrosine phosphatase
receptor type F (Ptprf/Accession no. NM_011213) with
39- and the A disintegrin and metalloprotease domain 19
(Adam19/Accession no. NM_009616) with 35 insertions.
Presumably owing to the smaller integration target and to
the need for productive insertions to occur downstream of
signal sequences or transmembrane domains, the secretory
gene trap hot spots were twice as frequent and averaged
twice as many insertions per hot spot as the conventional
gene trap hot spots (data not shown) (4). Interestingly,
although secretory hot spots were not related to gene size,
in a given hot spot, insertions tended to cluster in the larger
introns, conﬁrming their higher susceptibility to trapping (data
not shown) (16).
Figure 2. Comparison of the rates of trapping of secretory and standard gene trap vectors. GTSTs matching unique genes (e < 10
 6) were identified by using the
RefSeq database (rel. 13) and the BlastN algorithm. The number of novel genes hit by accumulating insertions was traced chronologically.
Figure 3. Correlation between secretory trap insertions and the number of individual genes per chromosome.
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Acquisition of a signal sequence by the Ceo fusion protein
predicts that trapped ES cells resistant to G418 should
also express CD2. To test this assumption, 10
4 ES
cells were infected with the U3Ceo virus and selected in
G418. Surviving cells were treated with a monoclonal anti-
CD2- antibody and analyzed by ﬂow cytometry. Figure 5
shows that only 20% of the trapped ES cells expressed
CD2, a frequency not entirely unexpected since other gene
Figure 4. Distribution of gene trap insertions according to the position of the trapped intron within genes. The data are based on NCBI mouse genome build 34 and
RefSeq database release 13.
Figure 5. CD2 expression by U3Ceo trapped ES cells. A total of 5 · 10




CD2 expression was estimated by flow cytometry after treating the cells with a FITC-conjugated sheep anti-mouse Fab02 antibody.
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phosphotransferase (bgeo) fusion gene yielded similar results.
Accordingly, in most screens only about 30% of the cell lines
isolated in G418 expressed b-galactosidase (b-gal) (4,16).
Collectively, these results indicate that the detection of
a reporter protein in the context of a neo fusion requires higher
levels of expression than the induction of G418 resistance.
Nevertheless, as has been shown previously for b-gal, the
CD2 marker may be useful for monitoring gene expression
in transgenic mice.
Secretory traps are highly mutagenic
To test the quality of Ceo trap induced mutations, we selected
10 ES cell lines with insertions in X-chromosomal genes
(Table 2). As the parental ES cell line is male derived,
these cell lines provided a haploid background for the muta-
tional analysis. As expected, all genes were expressed in
ES cells and in each case the trapped cell lines expressed
a fusion transcript as a result of splicing the upstream
exons to the gene trap cassette (Figure 6A). Quantitative
Table 2. List of the used ES cell lines harboring gene trap insertions in X-chromsomal genes
ES-cell line Vector Gene symbol Accession number Name Intron Captured
a
sequence
G024D09 U3Ceo Idh3g NM_008323 Isocitrate dehydrogenase 3 (NAD+), gamma 1 Mitochondr.
G047F01 U3Ceo Tmem32 NM_146234 Transmembrane protein 32 1 Signal
G049B05 U3Ceo Ndufa1 NM_019443 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 1
1 Signal
G067H01 U3Ceo 2610529C04Rik NM_025952 RIKEN cDNA 2610529C04 gene 1 Signal
P071A12 FlipRosaCeo Pdha1 NM_008810 Pyruvate dehydrogenase E1 alpha 1 9 Mitochondr.
P071D05 FlipRosaCeo Prdx4 NM_016764 Peroxiredoxin 4 5 Signal.
P071F11 FlipRosaCeo Ndufb11 NM_019435 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 11
1 Signal
P072A05 FlipRosaCeo Atp6ap2 NM_027439 ATPase, H+ transporting, lysosomal accessory
protein 2
8 Signal
P076F03 FlipRosaCeo Gla NM_013463 Galactosidase, alpha 5 Signal
P086B06 FlipRosaCeo 2610529C04Rik NM_025952 RIKEN cDNA 2610529C04 gene 1 Signal
aAccording to SmartP (version 4.1).
Figure 6. TranscriptionalanalysisofX-linkedmutationsintrappedEScelllines.(A)RT–PCRoffusiontranscriptsinducedbythegenetrapinsertionsusingtrapped
gene- and vector- specific primers. M, molecular weight marker (50 bp ladder). (B) Quantitative RT–PCR of wild-type transcripts expressed in the trapped ES cell
lines. Gene-specific primers were chosen in exons flanking the insertion sites (Supplementary Table 1 and Supplementary Figure 1). Results are means from three
independent experiments ± SD.
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eight cell lines the endogenous transcripts were reduced to
about 5% or less of wild-type levels. The residual wild-type
gene activity in most of these clones most likely reﬂects the
presence of some contaminating feeder cells. Indeed, as
exempliﬁed in Supplementary Figure 1 for the G024D09
and G067H01 cell lines, endogenous transcripts could be
reduced further by growing the cells in feederless
differentiation cultures. Collectively, the results suggest that
in most cases the Ceo trap insertions induce null mutations.
However, in two instances the trapped alleles were clearly
hypomorphic as they continued to express relatively high
levels (>20%) of endogenous transcript (Figure 6).
Hypomorphic alleles may also result from insertions into
downstream introns: for example in the 8th and 9th intron
of the ATPaseH+ transporting, lysosomal accessory protein
2 and the pyruvate dehydrogenase E1 alpha 1 genes,
respectively (Supplementary Table 1 and Supplementary
Figure 2). In these instances, the truncated endogenous
proteins may retain some function. Conversely, such
proteins could exert a dominant negative effect.
To investigate this further, we transferred the M076C04
and G033C05 ES cell lines to the mouse germline by
blastocyst injection. The M076C04 and G033C05 cell lines
contain U3Ceo insertions in the ﬁrst and 11th intron of the
C030019F02Rik and semaphorin-4B genes, respectively
(Figure 7A and B, top panels). In both cases, intercrossing
F1 heterozygous offspring yielded homozygous offspring
at a frequency consistent with a Mendelian inheritance pattern
of the disrupted transgenes. As shown in Figure 7, neither of
the homozygous F2 mice expressed wild type transcripts,
which should be equivalent to a null mutation. However,
although the mutated semaphorin-4B protein lost its entire
intracellular domain, we cannot exclude the possibility that
the truncated protein had retained some residual function.
In summary, the mutagenicity of Ceo traps is comparable
to that of other gene trap vectors (4,8).
DISCUSSION
In the present study, we have validated a gene trap strategy for
inducing genome wide mutations in secretory pathway genes.
By employing a CD2/neomycinphosphotransferase fusion
gene (Ceo) in a retroviral gene trap vector, we have selected
for productive gene trap events that are largely dependent on
the acquisition of a signal sequence and/or a transmembrane
domain from an endogenous gene. Of the ES cell lines isolated
with these gene traps, 80% had insertions in secretory pathway
genes. Analysis of several insertions in X-chromosomal genes
and the passage of two trapped autosomal genes to the
mouse germline revealed that the secretory Ceo traps are
highly mutagenic in vitro and in vivo.
A similar strategy involving gene trap vectors that encode
a bgeo fusion protein along with a CD4 transmembrane
domain has been used previously to isolate ES cell lines
with mutations in secretory genes (8). However, the plasmid
vectors employed in that screen were not particularly efﬁcient
due to a high background of non-productive trapping events.
Indeed, <1 in 10 cell lines recovered after electroporation and
G418 selection harbored insertions in secretory genes (16),
a frequency almost an order of magnitude below that achieved
by the current vectors. While the reasons for the different
trapping efﬁciencies are not entirely clear, two factors
could have played a crucial role in generating the non-
productive trapping events. First, bgeo is about three times
larger than Ceo and is likely to be less stable in combination
with a signal sequence. Second, plasmid vectors delivered by
electroporation are sensitive to nucleases and undergo trunca-
tionsthatmayleadtoimpropersplicing(16).Moreover,unlike
the retroviruses, plasmid vectors can induce deletions within
thetargetDNA.Nevertheless,thesecretory plasmidtrapswere
used by the BayGenomics consortium to assemble a library of
 1200 ES cell lines with mutations in secretory genes (3)
(http://baygenomics.ucsf.edu). Of the  400 unique genes
trapped, 159 overlap with the Ceo library. By adding the
BayGenomics effort to the 717 unique genes trapped in this
screen, a total of 958 different genes were trapped in the
public domain, corresponding to  10% of all secretory
genes predicted by the ENSEMBL database. Most import-
antly, 525 (55%) of these genes have not been previously
trapped by conventional strategies, indicating that secretory
and conventional strategies are complementary. All trapped
Figure 7. Secretory gene disruption in transgenic mice. (A) Top: structure of
the C030019F02Rik gene as annotated by ENSEMBL and position of the gene
trap insertions (arrow). Bottom: northern blot analysis of C030019F02Rik
transcripts expressed in homozygous mice. 20 mg total RNAs extracted from
the brains of wild type (+/+) and mutant ( / ) mice were fractionated on 1%
formaldehyde/agarose gels and hybridized to a
32P-labeled full-length
C030019F02Rik c-DNA probe. (B) Top: structure of the semaphorin-4B gene
as annotated by ENSEMBL and position of the gene trap insertion (arrow).
Bottom: RT–PCR of transcripts expressed in wild type (+/+) and homozygous
mutant( / )embryosusingprimerscomplementarytothe11thand14thexon
of the semaphorin-4B gene. M, molecular weight marker (smart ladder).
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be ordered directly over the IGTC’s web page (http://www.
genetrap.org).
Analysis of the existing gene trap resources indicates that
gene trapping is more efﬁcient than gene targeting only up
to  40% of all mouse genes, after which the mutation rate
falls to a level comparable to gene targeting (6). However, a
recently published strategy involving the insertion of a gene
trap cassette into a target gene by homologous recombination
promises to be more efﬁcient than gene trapping even before
it reaches 40% saturation (17,18). As with gene trapping,
the selection of recombinants relies on gene expression,
yielding over 50% of correctly targeted events (18). In
addition to its efﬁciency, the strategy is attractive because it
uses generic cassettes that simplify the design of targeting
vectors.
We conclude that the gene traps described in this study
are well suited for both random and targeted mutagenesis
of secretory genes that are expressed in ES cells. Furthermore,
we believe that a balance between targeting and trapping
will be the most efﬁcient and cost-effective strategy for
generating a complete collection of null and conditional
mutations in mice. This balance needs to take into account
the progressively decreasing trapping rates on one hand, and
the effort required for designing and cloning individual
targeting vectors on the other.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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